Riluzole therapy in cervical dystonia

Movement Disorders

Volumn 17, Issue 1, 2002, Pages 198-200

  Müller, Jörg ^a   Wenning, Gregor K ^a   Wissel, Jörg ^a   Baldauf, Angelika ^a   Seppi, Klaus ^a   Brenneis, Christian ^a   Poewe, Werner ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; LIVER ENZYME; RILUZOLE; TETRABENAZINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSTONIA; FEMALE; HEAD MOVEMENT; HUMAN; LIVER DYSFUNCTION; MALE; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME; VIDEORECORDING;

ADULT; ANTICONVULSANTS; CERVICAL VERTEBRAE; DYSTONIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RILUZOLE;

EID: 0036460860     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1200     Document Type: Article

References (11)

1. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ. Epidemiology of focal and generalized dystonia in Rochester. Mov Disord 1988;3:188-194.
2. Jankovic J, Fahn S. Dystonic Disorders. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders, 2nd Ed. Baltimore: Williams and Wilkins; 1993:337-374.
3. Brin MF, Jankovic J, Comella C, Blitzer A, Tsui J, Pullman SL. Treatment of dystonia using botulinum toxin. In: Kurlan R, ed. Treatment of movement disorders. Philadelphia: Lippincott; 1995: 183-246.
4. Vitek JL, Chockkan V, Zhang J-Y, Kaneoke Y, Evatt M, DeLong MR, Triche S, Mewes K, Hashimoto T, Bakay RAE. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 1999;46:22-35.
5. Boraud T, Bezard E, Stutzmann JM, Bioulac B, Gross CE. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neurosci Lett 2000;281:75-78.
6. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999;81:163-221.
7. Tsui JK, Eisen A, Stoessel AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2: 245-247.
8. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, Delumeau JC, Meininger V, and the ALS/Riluzole Study Group-II. A confirmatory dose-ranging study of riluzole in ALS. Neurology 1996;47:S242-S250.
9. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RI, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
10. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G - the German Dystonia Study Group (GDSG). What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double-blind, placebo controlled, dose ranging study using Dysport®. J Neurol Neurosurg Psychiatry 1998;64:13-17.
11. Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet 1999; 353:1764-1765.